Vulvar CancerGroSNaPETNCT02969278
Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy
A study testing 18FDG-PET/TC and Sentinel node biopsy in people with Vulvar Cancer, run by Catholic University of the Sacred Heart at 1 site in Italy.
Trial summary
The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Vulvar Cancer
- What is being tested?
- 18FDG-PET/TC and Sentinel node biopsy
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteItaly
- Study dates
- Jul 2013to Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age> 18 years
- ECOG ≤ 2
- Adequate respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL/min according to the Cockroft formula)
- Patient psychologically able to follow the study procedures
- Signature of informed consent
- In addition, both major criteria and at least one of the minor criteria must be present:
Show all 17Show fewer
- MAJOR CRITERIA
- Vulvar carcinoma (stromal infiltration > 1 mm); Histotypes different from squamous are included
- Negative lymphnodes at preoperative imaging
- MINOR CRITERIA
- Vulvar lesion greater than 4 cm
- Multifocal or bilateral lesions
- Previous complete excisional biopsy of the vulvar lesion, with absent residual disease
- Previous neoadjuvant treatment (radiotherapy a/o sequential/concomitant chemotherapy)
- Previous treatment with radiotherapy a/o chemotherapy (sequential a/o concomitant) for previous vulvar cancer a/o other diseases
- Previous vulvar or inguinal surgery
- Infiltrating vulvar carcinoma with monolateral groin lymphnode involvement (N1) and contralateral N0
Who cannot join
- Allergy to egg proteins and albumin
- Pregnancy and breastfeeding
- Patients with impaired respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL / min according to the Cockroft formula)
- Patients with major depressive disorder
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Division of Gynecologic Oncology/Fondazione Policlinico Gemelli
Rome, Rome, 00168
Giorgia Garganese, MD, 00390630158545, ggarganese@gmail.com
Simona M Fragomeni, MD, 00390630158545, simona.fragomeni@gmail.com
About this study
Official title: Study on the Prediction of Groin Lymphonodal Status Through 18FDG-PET/CT Combined With Sentinel Lymph Node Biopsy in Bulky a/o Multifocal a/o Pretreated Vulvar Cancer, N0 at Conventional Imaging (GRO-SNaPET Study)
The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.
Read the detailed description
Vulvar carcinoma (VC) is a rare disease (4% of gynecological cancers) and the treatment is not yet universally defined. No official guidelines are currently available to define imaging techniques useful for staging. In the pre-operative evaluation of the pateints, imaging should assess nodal status; the available exams are:
- CT or MRI with contrast (abdominal and pelvic with caudal scans for inguinal regions)
- Inguinal ultrasound with US-guided biopsy/fine needle aspiration for suspicious lymph nodes.
The incidence of inguinal and pelvic lymph node metastasis not diagnosed at the pre-operative imaging is 10-35% as assessed after lymphadenectomy at pathology report.
Until 2009, the standard surgical treatment of vulvar cancer was represented by mono or bilateral systematic lymphadenectomy (at least 70% of N0 women underwent a radical surgery with the risk of severe morbidity related to the surgical procedure with no survival benefit).
Inguinal lymphadenectomy shows a high rate of local and systemic complications resulting in a longer hospitalization or recovery, as well as possible delays in adjuvant therapies.
Moreover, severe complications can lead to a further surgery.
Possibile complications described in literature are:
- Lymphedema (up to 70%)
- Infection and postoperative cellulitis (50%)
- Inguinal suture dehiscence (between 22 and 52%)
- Linfocysts (between 7 and 28%)
- Deep vein thrombosis (between 5 and 8%)
- Sepsis (1 -2%)
Since 2009, with the introduction and the validation of sentinel node biopsy (SNB), for some VC it is now possible to obtain a nodal staging with minimally invasive surgery and lower morbidity. However, the SNB technique is indicated if the tumor fits the following selection criteria:
- Infiltrating tumors with a diameter < 40 mm;
- Monofocal tumors;
- Tumors distant more than 1 cm from the midline
- Tumors near the midline with bilateral lymphatic drainage and intraoperative detection of at least one sentinel node for each groin.
Consequently in many tumors diagnosed as N0 at preoperative imaging, SNB technique is not indicated; these tumors still require systematic lymphadenectomy.
In this subset of patients it is important to identify new methods for preoperative evaluation of nodal status or to define a sub-category of patients for which the SNB could be applied.
Objective of the study is to verify, in patients actually off-label for SNB, the accuracy of 18FDG-PET/CT in predicting nodal status, as an indipendent method or associated with the standard pre-operative imaging and the mini-invasive surgical staging.
All patients are submitted to:
- Gynecologic visit
- Vulvar biopsy and possible pelvic examination under anesthesia with the definition of clinical extent of disease
- Evaluation of serum tumor markers: SCC and Ca125
- Inguinal ultrasound and possible US guided FNAC or FNAB on suspicious lymph nodes
- CT scan (abdomen and pelvis) with contrast
- 18FDG-PET/CT
- Lymphangioscintigraphy of inguinofemoral axis
Vulvar surgery may include:
- Wide resection of vulvar disease
- Emivulvectomy (anterior, posterior or lateral)
- Simple vulvectomy
- Radical or ultra-radical vulvectomy (with possible plastic reconstruction)
During inguinal surgery all patients will undergo:
- Sentinel node biopsy mono or bilateral followed by radical bilateral inguinal lymphadenectomy
Statistical analysis will help determine the accuracy and negative predictive value of FDG-PET/CT and sentinel node biopsy in predicting nodal status.
- Conditions
- Vulvar Cancer
- Being tested
- 18FDG-PET/TC, Sentinel node biopsy
- Keywords
- vulvar cancer, sentinel node biopsy, inguino-femoral lymphadenectomy, 18F FDG- PET/TC, guidelines, preoperative imaging
- Medical subject headings
- Vulvar Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
18FDG-PET/TCProcedure or surgery
Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
Sentinel node biopsyProcedure or surgery
Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
| Study group | Role | What they receive |
|---|---|---|
| Vulvar cancer patients cN0 unfit for sentinel node biopsy | Experimental | All invasive vulvar cancer patients with cN0 status:
* T > 4 cm;
* multicentric tumors (mono or bilateral);
* primary lesion completely excised during prior diagnostic surgery
* patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0
* previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy Receives: Procedure: 18FDG-PET/TC; Procedure: Sentinel node biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy and Negative Predictive Value of sentinel node biopsy in cN0 vulvar cancer patients that do not fit for the current indications
Measured: within the first 30 days after surgery
Secondary outcomes (1)
Accuracy and Negative Predictive Value of preoperative 18F FDG-PET/CT for the selection of cN0 patients.
Measured: within the first 60 days before surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2016 (estimated)
- Study startJul 2013
- Primary completionJul 2017 (estimated)
- Study completionJul 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vulvar CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Catholic University of the Sacred Heart
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Giovanni Scambia, Catholic University of the Sacred Heart
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02969278
- Sponsor's protocol ID
- GroSNaPET
- Acronym
- GroSNaPET
- Status last verified
- Nov 2016
- First submitted
- 17 Nov 2016
- Last updated
- 21 Nov 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Prediction of Groin Lymphonodal Status Through 18FDG-PET/CT Combined With Sentinel Lymph Node Biopsy in Bulky a/o Multifocal a/o Pretreated Vulvar Cancer, N0 at Conventional Imaging (GRO-SNaPET Study)
- ClinicalTrials.gov ID
- NCT02969278
- Acronym / sponsor ID
- GroSNaPET / GroSNaPET
- Conditions
- Vulvar Cancer
- Keywords
- vulvar cancer, sentinel node biopsy, inguino-femoral lymphadenectomy, 18F FDG- PET/TC, guidelines, preoperative imaging
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Catholic University of the Sacred HeartUniversity, hospital or other
- Study start
- Jul 2013
- Primary completion
- Jul 2017 (estimated)
- Study completion
- Jul 2017 (estimated)
- First posted
- 21 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.
Detailed description
Vulvar carcinoma (VC) is a rare disease (4% of gynecological cancers) and the treatment is not yet universally defined. No official guidelines are currently available to define imaging techniques useful for staging. In the pre-operative evaluation of the pateints, imaging should assess nodal status; the available exams are:
- CT or MRI with contrast (abdominal and pelvic with caudal scans for inguinal regions)
- Inguinal ultrasound with US-guided biopsy/fine needle aspiration for suspicious lymph nodes.
The incidence of inguinal and pelvic lymph node metastasis not diagnosed at the pre-operative imaging is 10-35% as assessed after lymphadenectomy at pathology report.
Until 2009, the standard surgical treatment of vulvar cancer was represented by mono or bilateral systematic lymphadenectomy (at least 70% of N0 women underwent a radical surgery with the risk of severe morbidity related to the surgical procedure with no survival benefit).
Inguinal lymphadenectomy shows a high rate of local and systemic complications resulting in a longer hospitalization or recovery, as well as possible delays in adjuvant therapies.
Moreover, severe complications can lead to a further surgery.
Possibile complications described in literature are:
- Lymphedema (up to 70%)
- Infection and postoperative cellulitis (50%)
- Inguinal suture dehiscence (between 22 and 52%)
- Linfocysts (between 7 and 28%)
- Deep vein thrombosis (between 5 and 8%)
- Sepsis (1 -2%)
Since 2009, with the introduction and the validation of sentinel node biopsy (SNB), for some VC it is now possible to obtain a nodal staging with minimally invasive surgery and lower morbidity. However, the SNB technique is indicated if the tumor fits the following selection criteria:
- Infiltrating tumors with a diameter < 40 mm;
- Monofocal tumors;
- Tumors distant more than 1 cm from the midline
- Tumors near the midline with bilateral lymphatic drainage and intraoperative detection of at least one sentinel node for each groin.
Consequently in many tumors diagnosed as N0 at preoperative imaging, SNB technique is not indicated; these tumors still require systematic lymphadenectomy.
In this subset of patients it is important to identify new methods for preoperative evaluation of nodal status or to define a sub-category of patients for which the SNB could be applied.
Objective of the study is to verify, in patients actually off-label for SNB, the accuracy of 18FDG-PET/CT in predicting nodal status, as an indipendent method or associated with the standard pre-operative imaging and the mini-invasive surgical staging.
All patients are submitted to:
- Gynecologic visit
- Vulvar biopsy and possible pelvic examination under anesthesia with the definition of clinical extent of disease
- Evaluation of serum tumor markers: SCC and Ca125
- Inguinal ultrasound and possible US guided FNAC or FNAB on suspicious lymph nodes
- CT scan (abdomen and pelvis) with contrast
- 18FDG-PET/CT
- Lymphangioscintigraphy of inguinofemoral axis
Vulvar surgery may include:
- Wide resection of vulvar disease
- Emivulvectomy (anterior, posterior or lateral)
- Simple vulvectomy
- Radical or ultra-radical vulvectomy (with possible plastic reconstruction)
During inguinal surgery all patients will undergo:
- Sentinel node biopsy mono or bilateral followed by radical bilateral inguinal lymphadenectomy
Statistical analysis will help determine the accuracy and negative predictive value of FDG-PET/CT and sentinel node biopsy in predicting nodal status.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Vulvar cancer patients cN0 unfit for sentinel node biopsy | Experimental | Procedure: 18FDG-PET/TC, Procedure: Sentinel node biopsyAll invasive vulvar cancer patients with cN0 status: * T > 4 cm; * multicentric tumors (mono or bilateral); * primary lesion completely excised during prior diagnostic surgery * patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0 * previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Age> 18 years
- ECOG ≤ 2
- Adequate respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL/min according to the Cockroft formula)
- Patient psychologically able to follow the study procedures
- Signature of informed consent
Key exclusion criteria (4 listed)
- Allergy to egg proteins and albumin
- Pregnancy and breastfeeding
- Patients with impaired respiratory, hepatic, cardiac, bone marrow and renal function (creatinine clearance> 60 mL / min according to the Cockroft formula)
- Patients with major depressive disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 18FDG-PET/TCNuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes | Procedure or surgery | Vulvar cancer patients cN0 unfit for sentinel node biopsy |
| Sentinel node biopsyIntradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye. | Procedure or surgery | Vulvar cancer patients cN0 unfit for sentinel node biopsy |
Primary outcome
Accuracy and Negative Predictive Value of sentinel node biopsy in cN0 vulvar cancer patients that do not fit for the current indications
Time frame: within the first 30 days after surgery
1 secondary outcome
Accuracy and Negative Predictive Value of preoperative 18F FDG-PET/CT for the selection of cN0 patients.
Time frame: within the first 60 days before surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2016.
- Individual participant dataSharing planned: No
Related trials for Vulvar Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Active, not recruiting
Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
Vulvar Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Active, not recruiting
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8
Active, not recruitingPhase 2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Ovarian Neoplasms, Endometrial Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Division of Gynecologic Oncology/Fondazione Policlinico Gemelli
Rome, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 18FDG-PET/TC and Sentinel node biopsy in people with Vulvar Cancer, run by Catholic University of the Sacred Heart at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy and Negative Predictive Value of sentinel node biopsy in cN0 vulvar cancer patients that do not fit for the current indications (time frame: within the first 30 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2016.